All the fundraising deals in the femtech market (from Q2 2025 to Q2 2026)
Download our beautiful pitch about the femtech market
In our femtech market deck, you will find everything you need to understand the market
Femtech startups announced 52 funding rounds worth $846.11 million from Q2 2025 through Q2 2026.
Funding in the femtech market covered fertility care, menopause treatment, breast cancer screening, maternal health, pelvic health and menstrual products.
Q2 2026 recorded the highest number of femtech funding deals, while Q3 2025 attracted the most capital.
And if you want to better understand this new industry, you can download our pitch covering the femtech market.
Insights
- The femtech market raised $846.11 million across 52 deals during the five-quarter period, which represents an average funding round of $16.27 million.
- Q2 2026 recorded 16 femtech deals, the highest quarterly count, but its average round was only $9.81 million, the lowest level in the period.
- Q3 2025 attracted $255.70 million, or 30.2% of all femtech funding, supported by four rounds worth at least $44 million each.
- Fertility, IVF and reproductive biotechnology attracted $277.55 million, representing 32.8% of all funding in the femtech market.
- The three leading femtech categories captured $619.63 million, or 73.2% of the total capital raised during the period.
- Midi Health raised $150 million across two rounds, equal to 17.7% of all recorded femtech funding.
- The ten largest femtech rounds represented $525 million, or 62.0% of total funding, showing that large clinical companies still attract most capital.
- Q2 2026 was more diversified than earlier quarters because its largest round represented only 19.1% of quarterly femtech funding.
- Regulated products attracted many of the largest rounds, including medicines, cancer tests, prescription wearables, prenatal diagnostics and IVF laboratory systems.
This market map, featured in our femtech market deck, highlights top companies and startups in the femtech market
Summary table of the funding deals in the femtech market (last 5 quarters)
We define the femtech market as technology-enabled products and services that address women's reproductive and other female-specific health needs.
We include solutions focused on menstrual and cycle health, fertility and contraception, pregnancy and postpartum, menopause, pelvic and sexual health, and clinically oriented tools for conditions that predominantly or uniquely affect women, such as breast and gynecological cancers.
We exclude general-purpose health, wellness, fitness, mental health and consumer apps that are not specifically designed around women's biology, care pathways or life stages.
You can also read our detailed analysis to understand how funding activity in the femtech market has evolved over the last few years.
Also, you should know that we have a dedicated page, updated weekly, with all the latest fundraising deals in the femtech market.
| Name | What they do | Amount in $ | Quarter |
|---|---|---|---|
| Escala Medical | Develops a minimally invasive device for repairing pelvic-organ prolapse. | $4.5M | Q2 2025 |
| Joii | Uses smart menstrual products to measure flow and identify unusual patterns. | $2.6M | Q2 2025 |
| Samphire Neuroscience | Develops a neurostimulation wearable for PMS, menstrual pain and related symptoms. | $5M | Q2 2025 |
| Magcath | Develops a minimally invasive medical device for female urinary incontinence. | $0.58M | Q2 2025 |
| UVISA | Develops an at-home light-therapy device for recurrent vaginal infections. | $0.65M | Q2 2025 |
| Hormona | Combines at-home hormone testing with an app that explains hormonal patterns. | $8.8M | Q2 2025 |
| Overture Life | Builds robotic systems that automate procedures inside IVF laboratories. | $20.6M | Q2 2025 |
| ReproNovo | Develops medicines for infertility, uterine conditions and reproductive disorders. | $65M | Q2 2025 |
| Ovo Labs | Develops treatments designed to improve egg quality and IVF success. | $5M | Q2 2025 |
| Cofertility | Provides egg freezing and egg donation through a shared-cost model. | $7.25M | Q2 2025 |
| Midi Health | Provides virtual clinical care for menopause, perimenopause and women's midlife health. | $50M | Q2 2025 |
| Seven Starling | Provides mental-health treatment for fertility, pregnancy, loss and postpartum needs. | $8M | Q3 2025 |
| Gameto | Develops stem-cell-based reproductive treatments for egg maturation and IVF. | $44M | Q3 2025 |
| Solence | Provides digital treatment and lifestyle support specifically for PCOS. | $1.7M | Q3 2025 |
| Ovasave | Provides at-home fertility testing and specialist consultations across the Middle East. | $1.2M | Q3 2025 |
| Plenna | Operates Mexican clinics for gynecology, reproductive health and preventive care. | $6M | Q3 2025 |
| BeSound | Provides ultrasound breast screening for women with dense breast tissue. | $6.8M | Q3 2025 |
| Visana Health | Provides virtual care for endometriosis, PCOS, menopause and related conditions. | $24M | Q3 2025 |
| Diana Health | Operates maternity and women's-health programs in partnership with hospitals. | $55M | Q3 2025 |
| Conceivable Life Sciences | Builds automated IVF laboratories using artificial intelligence and robotics. | $50M | Q3 2025 |
| Mercy BioAnalytics | Develops blood tests designed to detect ovarian cancer earlier. | $59M | Q3 2025 |
| Pluro Fertility & IVF | Builds and partners with fertility clinics across Indian cities. | $15M | Q4 2025 |
| Emm | Develops a connected menstrual cup that tracks flow and cycle patterns. | $9M | Q4 2025 |
| FamilyWell Health | Embeds maternal mental-health services inside women's-health practices. | $8M | Q4 2025 |
| Metri Bio | Develops new medicines specifically for the treatment of endometriosis. | $5M | Q4 2025 |
| Inito | Sells a home fertility monitor that measures four reproductive hormones. | $29M | Q4 2025 |
| IVFmicro | Develops microfluidic technology designed to improve embryo culture and IVF results. | $4.4M | Q4 2025 |
| Micro Inno | Develops portable imaging equipment for gynecological examinations and diagnostics. | $5M | Q4 2025 |
| Clairity | Uses mammograms and artificial intelligence to predict future breast-cancer risk. | $43M | Q4 2025 |
| BrightHeart | Uses artificial intelligence to detect fetal heart abnormalities during prenatal ultrasounds. | $11.9M | Q1 2026 |
| Feminai | Develops a wearable for breast-cancer screening outside traditional hospitals. | $6M | Q1 2026 |
| Xella Health | Uses menstrual fluid and multi-omics to develop women-specific diagnostic tests. | $3.7M | Q1 2026 |
| Pinky Promise | Runs an AI-assisted digital clinic for women's health in India. | $1M | Q1 2026 |
| Origin | Provides pelvic-floor therapy for pregnancy, postpartum, incontinence and sexual health. | $21M | Q1 2026 |
| Midi Health | Provides virtual clinical care for menopause, perimenopause and women's midlife health. | $100M | Q1 2026 |
| 28x | Develops a private period tracker that processes data on the user's device. | $1.5M | Q1 2026 |
| ONTO Health | Combines artificial intelligence, diagnostics and physician-led fertility care. | $20M | Q2 2026 |
| Osteoboost Health | Develops a prescription wearable that helps preserve postmenopausal bone density. | $8M | Q2 2026 |
| Future Fertility | Uses artificial intelligence to assess egg quality for fertility treatments. | $4.1M | Q2 2026 |
| HealthFab | Produces reusable menstrual underwear and period-care products in India. | $2.4M | Q2 2026 |
| ScreenPoint Medical | Develops artificial intelligence software that helps radiologists detect breast cancer. | $14M | Q2 2026 |
| Wavelet Medical | Develops AI-powered fetal-brain monitoring for labor and delivery. | $7M | Q2 2026 |
| Flora Fertility | Provides Canadian insurance for fertility testing, medication, IUI and IVF. | $5M | Q2 2026 |
| SimpliFed | Provides virtual lactation, infant-feeding and maternal support through health plans. | $10.8M | Q2 2026 |
| Mammogen | Develops an RNA blood test for breast-cancer detection. | $30M | Q2 2026 |
| Dioseve | Develops stem-cell technology for egg maturation and fertility treatment. | $7M | Q2 2026 |
| Rejoni | Develops a uterine hydrogel that may prevent adhesions after surgery. | $25M | Q2 2026 |
| Clair Health | Develops a wearable for continuous monitoring of female hormones. | $11.6M | Q2 2026 |
| Ovum | Combines symptoms, medical records and female-health data in one platform. | $2.6M | Q2 2026 |
| June Health | Provides women's healthcare through employers and partner organizations. | $1.75M | Q2 2026 |
| Intu Diagnostics | Develops a lab-free molecular HPV test for cervical-cancer screening. | $1.18M | Q2 2026 |
| Oli / Baymatob | Develops a wearable that monitors maternal and fetal signals during labor. | $6.5M | Q2 2026 |
In our femtech market deck, we identify pain points entrepreneurs should prioritize
How has funding activity in the femtech market changed over time?
Q3 2025 attracted the most femtech funding, with $255.70 million, because Mercy BioAnalytics, Diana Health, Conceivable Life Sciences and Gameto each raised at least $44 million.
Q4 2025 attracted the least capital, at $118.40 million, while Q1 2026 recorded the fewest deals, with seven rounds.
Femtech funding increased by 8.2% from Q1 2026 to Q2 2026, but Q2 2026 funding remained 7.7% below the amount raised one year earlier in Q2 2025.
Without the largest deal from each quarter, the femtech market raised about $549.11 million across 47 deals. The adjusted average was $11.68 million, which shows a steadier market beneath the largest rounds.
| Quarter | Number of deals | Total raised ($) | Comment |
|---|---|---|---|
| Q2 2025 | 11 | $169.98M | ReproNovo and Midi Health represented most of the quarter's femtech funding. |
| Q3 2025 | 10 | $255.70M | Four clinical and fertility companies raised rounds worth at least $44 million. |
| Q4 2025 | 8 | $118.40M | Clairity and Inito led a quieter quarter with no deal above $50 million. |
| Q1 2026 | 7 | $145.10M | Midi Health supplied most of the capital through its $100 million Series D. |
| Q2 2026 | 16 | $156.93M | The femtech market recorded more deals, but funding was spread across smaller rounds. |
| All quarters | 52 | $846.11M | Femtech funding covered a broad mix of clinical care, diagnostics, devices and biotechnology. |
This chart, included in our femtech market deck, shows how Flo Health is capturing share in femtech
Which startups in the femtech market raised the largest rounds over the last months?
These startups raised the most recently in the femtech market:
- Midi Health raised $100 million to expand women's care across more life stages, recruit clinicians and develop artificial intelligence tools.
- ReproNovo raised $65 million to move its infertility and reproductive-health medicines through clinical development.
- Mercy BioAnalytics raised $59 million to validate and prepare the commercial launch of its ovarian-cancer blood test.
- Diana Health raised $55 million to bring its maternity and women's-health programs to more hospitals.
- Midi Health raised $50 million to expand nationally, recruit providers and develop services for women's midlife health.
- Conceivable Life Sciences raised $50 million to launch and expand automated IVF laboratories.
- Gameto raised $44 million to advance clinical programs for egg maturation, IVF and ovarian health.
- Clairity raised $43 million to commercialize its breast-cancer risk platform and connect it with hospital systems.
- Mammogen raised $30 million to complete clinical validation of its RNA-based breast-cancer blood test.
- Inito raised $29 million to improve its fertility monitor, expand distribution and develop new products.
And, yes, we do cover most of them in our our beautiful pitch about the femtech market.
You may also want to check our ranking of the most funded startups in the femtech market as well as our list of the most valued startups.
This chart, included in our femtech market deck, shows annual funding in femtech startups
Is the femtech market shifting toward smaller or bigger deals?
The average femtech funding round was $16.27 million across the full five-quarter period.
The quarterly average ranged from $9.81 million in Q2 2026 to $25.57 million in Q3 2025. The difference came mainly from the number of large clinical and biotechnology rounds announced in each quarter.
Without the largest deal from each quarter, the femtech market had an average round of about $11.68 million, suggesting that typical deal sizes were more stable.
| Quarter | Number of deals | Average deal size | Deals below $2M | Deals above $50M |
|---|---|---|---|---|
| Q2 2025 | 11 | $15.45M | 2 | 1 |
| Q3 2025 | 10 | $25.57M | 2 | 2 |
| Q4 2025 | 8 | $14.80M | 0 | 0 |
| Q1 2026 | 7 | $20.73M | 2 | 1 |
| Q2 2026 | 16 | $9.81M | 2 | 0 |
| All quarters | 52 | $16.27M | 8 | 4 |
This chart, included in our femtech market deck, compares the main business model options for menopause telehealth platforms
How concentrated was funding activity in the femtech market?
Funding concentration changed sharply between quarters. The largest femtech deal represented 68.9% of Q1 2026 funding, but only 19.1% of Q2 2026 funding.
This shift means Q2 2026 had a broader funding base, with capital spread across 16 companies and several femtech categories.
| Quarter | Number of deals | Top 1 | Top 3 | Top 10 |
|---|---|---|---|---|
| Q2 2025 | 11 | 38.2% | 79.8% | 99.7% |
| Q3 2025 | 10 | 23.1% | 64.1% | 100.0% |
| Q4 2025 | 8 | 36.3% | 73.5% | 100.0% |
| Q1 2026 | 7 | 68.9% | 91.6% | 100.0% |
| Q2 2026 | 16 | 19.1% | 47.8% | 89.1% |
| All quarters | 52 | 11.8% | 26.5% | 62.0% |
This chart, featured in our femtech market deck, illustrates how revenue is divided among customer segments in the femtech market
Which categories in the femtech market received the most funding?
Fertility, IVF and reproductive biotechnology raised $277.55 million, or 32.8% of total femtech funding. Investors supported the full fertility chain, from medicines and laboratory systems to clinics, insurance and home testing.
Menopause and hormonal health raised $182.10 million, or 21.5% of total funding. Midi Health accounted for $150 million of this category through two large rounds.
Breast and gynecological oncology raised $159.98 million, or 18.9% of total funding. The category attracted capital for blood tests, imaging software, risk prediction and cervical-cancer screening.
| Category name | Number of deals | Total raised ($) | Startups and amount |
|---|---|---|---|
| Fertility, IVF and reproductive biotechnology | 14 | $277.55M | Overture Life ($20.6M), ReproNovo ($65M), Ovo Labs ($5M), Cofertility ($7.25M), Gameto ($44M), Ovasave ($1.2M), Conceivable Life Sciences ($50M), Pluro Fertility & IVF ($15M), Inito ($29M), IVFmicro ($4.4M), ONTO Health ($20M), Future Fertility ($4.1M), Flora Fertility ($5M) and Dioseve ($7M). |
| Menopause and hormonal health | 7 | $182.10M | Hormona ($8.8M), Midi Health ($50M and $100M), Xella Health ($3.7M), 28x ($1.5M), Osteoboost Health ($8M) and Clair Health ($11.6M). |
| Breast and gynecological oncology | 7 | $159.98M | BeSound ($6.8M), Mercy BioAnalytics ($59M), Clairity ($43M), Feminai ($6M), Mammogen ($30M), ScreenPoint Medical ($14M) and Intu Diagnostics ($1.18M). |
This chart, included in our femtech market deck, shows how cycle tracking app technology has evolved over time
Who are the biggest investors in the femtech market?
ARTIS Ventures participated in two femtech deals worth a combined $70 million. Both investments supported automated or technology-enabled fertility care.
.406 Ventures participated in two women's-health care deals worth a combined $63 million. The investments covered hospital-based maternity care and maternal mental health.
Portfolia participated in two femtech deals worth a combined $52 million. The investments covered reproductive biotechnology and postmenopausal bone health.
Overwater Ventures participated in two femtech deals worth a combined $50.8 million. The investments covered fertility biotechnology and breast screening.
Disclaimer: this investor list may be incomplete; we focus on publicly disclosed lead and prominent recurring investors, so some frequent minority participants may be underrepresented. "Total funded" does not represent the amount personally invested by an individual investor. Instead, it refers to the aggregate amount raised across all fundraising rounds in which the investor participated.
| Investor | Number of deals | Total funded ($) | Startups |
|---|---|---|---|
| ARTIS Ventures | 2 | $70M | Conceivable Life Sciences and ONTO Health |
| .406 Ventures | 2 | $63M | Diana Health and FamilyWell Health |
| Portfolia | 2 | $52M | Gameto and Osteoboost Health |
| Overwater Ventures | 2 | $50.8M | Gameto and BeSound |
This chart, included in our femtech market deck, shows how fertility app adoption has driven growth in the femtech market over time
Related blog posts
- All the funding deals announced in the femtech market
- Which companies have raised the most funding in the femtech market?
- How strong is fundraising in the femtech market right now?
